Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for a sum of up to $32m, which includes contingent payments of up to $17m based on commercial milestones and other factors.
29 Oct 2018
24 Oct 2018
28 Sep 2018
Dova Pharmaceuticals, Salix Pharmaceuticals and its parent company Bausch Health Companies have entered into an exclusive agreement to co-promote Dova’s Doptelet (avatrombopag) in the US.
20 Sep 2018
Shield Therapeutics and Norgine have entered into an exclusive licence agreement in Europe, Australia and New Zealand, under which Norgine will commercialise Feraccru, Shield’s approved product for the treatment of iron deficiency in adults.
06 Jun 2017
Perrigo said its current CEO John Hendrickson is retiring and it has started a search for a replacement.
13 Feb 2017
Sanofi has agreed to divest five of its over-the-counter consumer healthcare products in Europe to French pharma firm Ipsen for €83m.